Share on

Multiple myeloma (MM) is a heterogeneous disease with varying survival outcomes depending on the presence of certain genetic abnormalities. Common abnormalities include

  • trisomies
  • translocations involving chromosome 14
  • amplifications or deletions of chromosomes 1, 13, and 17.

Occurring in approx. 15% of patients with multiple myeloma, t(11;14) is considered a standard risk abnormality. Yet, recent data suggest that the prognosis may be inferior to what had been expected. This is of particular relevance as new therapeutic options such as the BCL-2 inhibitor venetoclax has been shown to be effective in t(11;14) pts.

Conclusions: 

This study is the first to examine the outcomes of a large group of myeloma patients with t(11;14) abnormality.

  • Patients receiving a combination of a  proteasome inhibitory (PI) and an immunomodulatory drug (IMiD) appear to have the best survival outcomes.
  • Patients receiving an early stem cell transplant appear to have excellent survival with median overall survival (OS) approaching 10 years.

Additional patients are being accrued to this study. Also, additional analysis examining the variables affecting response duration and survival will be presented.

Authors: 

Brian G. Durie, Hartmut Goldschmidt, Maria-Victoria Mateos, Veronica Gonzalez, Juan Du, Kihyun Kim, Giampaolo Merlini, Silvia Mangiacavalli, Chang Ki Min, Meletios A. Dimopoulos, Efstathios Kastritis, Heinz Ludwig, Graca Esteves, Hiroshi Handa, Fernando Escalante, Carlos Fernández de Larrea Rodríguez, Michel Delforge, Chris Cameron, S. Vincent Rajkumar, Shaji Kumar; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Heidelberg, Heidelberg, Germany; University of Salamanca Hospital/IBSAL, Salamanca, Spain; University Hospital of Salamanca, Salamanca, Spain; Department of Hematology, Myeloma & Lymphoma Center, Shanghai Chang Zheng Hospital, Shanghai, China; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Scientific Institute Policlinico San Matteo, University of Pavia, Pavia, Italy; Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; National and Kapodistrian University of Athens, Athens, Greece; National and Kapodistrian University of Athens School of Medicine, Athens, Greece; Wilhelminen Cancer Research Institute, Wilhelminenspital, Department of Medicine, Center of Oncology, Hematology and Palliative Care, Vienna, Austria; Centro Hospitalar Lisboa Norte, Lisboa, Portugal; Gunma University, Gunma, Japan; Complejo Asistencial Universitario de León, Leon, Spain; Hospital Clínic de Barcelona., Barcelona, Spain; UZ Leuven, Leuven, Belgium; Cornerstone Research Group, Inc., Burlington, ON, Canada; Mayo Clinic, Rochester, MN


Abstract No:
8015

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 8015)

Previous Post
First clinical study of iberdomide, a CELMoD, in pts with relapsed/refractory multiple myeloma
Next Post
Belantamab mafodotin anti-BCMA ADC

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.